Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

 Key Statistics

Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO

 Company News
Halozyme Therapeutics, Inc. (HALO) Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors 1/21/2015 10:18:49 AM
Halozyme Therapeutics, Inc. (HALO) Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference 1/12/2015 9:55:58 AM
Halozyme Therapeutics, Inc. (HALO) Provides Agenda Highlights For Analyst And Investor Meeting 1/7/2015 8:55:06 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 10:56:37 AM
Halozyme Therapeutics, Inc. (HALO) Appoints Athena Countouriotis, M.D. As Chief Medical Officer 1/5/2015 8:35:02 AM
Halozyme Therapeutics, Inc. (HALO) To Host Analyst And Investor Meeting 12/30/2014 7:35:23 AM
Halozyme Therapeutics, Inc. (HALO) Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 12/19/2014 8:41:41 AM
Halozyme Therapeutics, Inc. (HALO) Strikes $581 Million R&D Pact With Johnson & Johnson (JNJ) 12/17/2014 9:02:32 AM
Halozyme Therapeutics, Inc. (HALO) Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting 12/12/2014 7:55:46 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The 25th Annual Oppenheimer Healthcare Conference 12/5/2014 12:49:01 PM